| Literature DB >> 24518747 |
D T Dibaba1, P Xun1, K He1.
Abstract
BACKGROUND/Entities:
Mesh:
Substances:
Year: 2014 PMID: 24518747 PMCID: PMC3975661 DOI: 10.1038/ejcn.2014.7
Source DB: PubMed Journal: Eur J Clin Nutr ISSN: 0954-3007 Impact factor: 4.016
Figure 1Process of study selection for the meta-analyses.
Characteristics of 9 cross-sectional analyses and 1 longitudinal analysis included in the study
| Source | Participants (n) | Males (%) | Age, | Exposure | Exposure | Outcome | Adjusted | Reported measures of |
|---|---|---|---|---|---|---|---|---|
| King D, | 5,021 | 25.4 | ≥17 | Dietary magnesium intake was derived from the 24 hour recall information for each respondent using the NHANES Computer assisted dietary interview (CADI) system | Four groups based on RDA | CRP was analyzed using a high sensitivity assay technique that quantifies CRP by latex-enhanced nephlometry. | BMI, smoking, income level, alcohol consumption, exercise, and medical conditions like congestive heart failure, coronary heart disease, angina, heart attack, diabetes and hypertension. | ORs with 95% CIs |
| Song Y, | 11,686 | 0 | ≥45 | Dietary Magnesium was assessed by semi quantitative FFQ. | Quintiles (median, mg/day): | CRP was measured by a validated high-sensitivity assay (Denka Seiken, Nigata, Japan). | Age, BMI, smoking, exercise, alcohol, total calorie intake, multivitamin use, diabetes, hypertension, high cholesterol, and parental history of MI before 60 years of age and dietary intakes of total fat, cholesterol, folate, glycemic loadand fiber. | Geometric Means with 95%CIs |
| Bo S, | 1,653 | 47.2 | 54.6±5.7 | Dietary magnesium was assessed by semi quantitative FFQ. | Tertiles (Median intake with 95% CIs, mg/day): | Serum CRP was measured with a high-sensitivity CRP latex agglutination method on HITACH 911 Analyzer (Sentinel Ch., Milan, Italy). | Age, sex, BMI, smoking, level of physical activity, alcohol consumption, dietary total energy intake, and percentage of total fat and fiber intake. | ORs with 95%CIs, Medians with 95%CIs, and beta coefficients |
| King D, | 5,007 | 51.4 | 6–17 | Secondary data on dietary magnesium intake was from NHANES 1999–2002. | Three groups based on RDA1 | High sensitivity CRP was measured as part of the NHANES 1999–2002 physical and laboratory examination. | Age, sex, race, income level, exercise, BMI and dietary intakes of fiber and total energy. | ORs with 95%CIs |
| Song Y, | 657 | 0 | 56 (43–69) | Dietary magnesium was assessed by semi quantitative FFQ. | Quintiles (median, mg/day): | Blood CRP was measured with a latex-enhanced turbidimetric assay on a Hitachi 911. | Age, smoking status, physical activity, alcohol consumption, total energyintake, menopausal status, postmenopausal hormone use, and BMI. | Geometric means with 95%CIs, and beta coefficients with SEs |
| Chacko SA, | 3,713 | 50–79 | 0 | Dietary magnesium, was assessed by semi quantitative FFQ. | Quintiles (median, mg/day): | hs-CRP was measured on a chemistry analyzer (Hitachi 911; Roche Diagnostics, Indianapolis, IN) using an immunoturbidimetri-c assay with reagents and calibrators (Denka Seiken, Niigata, Japan). | Age, race, ethnicity, clinical center, time of blood draw, smoking, alcohol, energy expenditure from recreational physical activity /week, total energy intake, BMI, case-control status and dietary intakes of fiber, fruit and vegetable, folate , saturated and trans fat | Geometric means with 95%CIs, beta coefficients with SEs |
| de Oleivera Otto M, | 5,181 | 45–84 | 47.6 | Dietary magnesium measured by MESA FFQ. | Quintiles (mg/day): | Plasma CRP was measured with a particle enhanced immunephelometric assay by a BNII nephelometer (high-sensitivity CRP; Dade Behring). | Age, sex,, race-ethnicity, total energy intake, field center, education, physical activity, alcohol consumption, smoking, fiber intake and dietary supplement use. | Geometric Means with 95%CIs |
| Guerrero-Romero F, | 371 | 23–52 | 27 | Serum magnesium was measured by colorimetric method. | Serum Magnesium quartiles (mg/dl) Lowest, 2nd and 3rd and Highest | CRP was measured by automated microparticle enzyme immunoassay (Imx, Abbot Laboratories, USA). | Age, sex, BMI and Glucose Tolerance status | Correlation coefficient (r), and OR on continuous scale with 95%CIs |
| Rodriguez-Morán M, | 488 | 50.8 | 10–13. | Serum magnesium concentrations were measured using a colorimetric method. | Tertiles magnesium (mg/dl) mean (SD): | High sensitive CRP was measured by automated micro particle enzyme immunoassay (Imx, Abbot Laboratories, Minneapolis, MN, USA). | BMI and body fat percentage. | OR with 95%CI, and mean with SD |
| Kim D, | 4,497 | 18–30 | 42.9 | Dietary magnesium intake was assessed by using a validated interview -administered CARDIA Diet History Questionnaire. | Quintiles of magnesium intake (mg/day): | High sensitive CRP was measured at at years 7,15 and 20 with a nephelometry-based high throughput assay. | Age, sex, ethnicity, study center, education, smoking status, alcohol consumption, physical activity, family history of diabetes, BMI, systolic Blood pressure, energy intake, dietary intake of saturated fat, and crude fiber. | Log transformed median , beta coefficients with 95%CIs |
Abbreviations: BMI: body mass index; CARDIA: Coronary Artery Risk Development in Young Adults; CI: confidence interval; CRP: C-reactive protein; MESA: Multi-Ethnic Study of Atherosclerosis; NHANES: National Health and Nutritional Examination Survey; NHS: Nurse Health Study; OR: odds ratio; RDA: Recommended Dietary Allowance;SD: standard deviation; SE: standard error; WHI-OS: Women’s Health Initiative- Observational Study; WHS: Women Health Study.
Magnesium RDA (mg/day) for both males and female: 130for those aged 6–8years old, 240 for those aged 9–13 years old; for males: 410 for those aged 14–18years, for females: 360 for those aged 14–18 years
Randomized controlled trials investigating the effect of magnesium supplementation on CRP in humans.
| Study | Country | Intervention group | Control group | Duration | Outcome Measure | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| n/N | Male, % | Age, year | Treatment | n/N | Male, % | Age, year | Treatment | ||||
| Almoznino-Sarafian, et al., 2007( | Israel | 17/17 | 52.9 | 71.0±7.8 | Oral magnesium citrate: 300 mg/day | 18/18 | 55.6 | 72.38 | Untreated Controls | 5 weeks | ln(CRP) ± SD; Pearson’s correlation coefficient |
| Chacko, et al., 2010( | USA | 13/14 | 71 | 44.4 ±13.0 | Oral magnesium citrate: 500 mg/day | 13/14 | 71 | 44.4 ± 13.0 | Placebo | 4 weeks | Geometric mean (95%CI) |
| Nielsen, et al., 2010( | USA | 46/50 | 22 | 51–85 | Oral magnesium citrate: 320 mg/day | 49/50 | 22 | 51–85 | Placebo (Sodium Citrate) | 8 weeks | Change in mean CRP (increase/decrease) |
| Rodriguez-Hernandez, et al., 2010( | Mexico | 15/20 | 0 | 30–65 | Oral Solution containing 50ml of 5% Magnesium Chloride (equivalent to 450 mg/day elemental magnesium) | 15/18 | 0 | 30–65 | Control | 4 months | Mean CRP ± SD; OR for reduction in CRP |
| Mosleh, et al., 2012( | Iran | 35/37 | 0 | 46.3±4.2 | Oral Magnesium Oxide: 250mg/day | 34/37 | 0 | 46.3±4.2 | Placebo | 8 weeks | Median (IQR) for CRP |
Abbreviations: n in n/N is the number of participants who completed the study in each arm; and N is the number of participants who started the study in each arm; CRP: C-reactive protein; IQR: inter-quartile range; SD: standard deviation.
Figure 2Meta-regression for modeling ln(CRP)levels against dietary magnesium intake from four cross-sectional studies. The dots represent observations from each quintile relating ln(CRP) to dietary magnesium intake. Size of dot is proportional to the inverse of squared standard error of ln(CRP).